IONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodies
Potent antibodies shown to retain binding to major COVID-19-causing “South African” variant
Articles by IONTAS
IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement with Quell Therapeutics
Diverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline
IONTAS and Adaptate Biotherapeutics Collaborate to Identify Optimized Antibodies for Novel Cancer Targets
The agreement is to generate and optimize antibodies for novel immuno-oncology targets
IONTAS Signs Collaboration Agreement with LG Chem to Identify Therapeutic Oncology Leads
IONTAS Limited announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd.
Iontas Awarded $737K from Innovate UK to Develop Therapies for Chronic Pain Management
Funding will be used to further develop IONTAS’ ion-channel targeting KnotBody antibody platform to block pain transmission via Nav1.7
IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads
IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE Antibodies for Cancer Targets
New project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study